To investigate the possibility of differing roles for cyclins D1 and D
2 in breast epithelial cells, we examined the expression, cell cycle r
egulation and activity of these two G(1) cyclins in both 184 normal br
east epithelial cells and T-47D breast cancer cells. Synchromisation s
tudies in 184 cells demonstrated that cyclin D1 and cyclin D2 were dif
ferentially regulated during G(1), with cyclin D2 abundance increasing
by 3.7-fold but only small changes in cyclin D1 abundance observed. T
he functional consequences of increased cyclin D2 expression were exam
ined in T-47D cells, which express no detectable cyclin D2, Induced ex
pression of cyclin D2 resulted in increases in cyclin E expression, pR
B phosphorylation and the percentage of cells in S-phase, while consti
tutive expression resulted in a consistent trend toward reduced depend
ence on serum for continued proliferation. Thus, cyclin D2 is a positi
ve regulator of G(1) progression in breast cells analogous to the well
-documented effects of cyclin D1. Indeed, equimolar concentrations of
inducible cyclin D1 and D2 resulted in quantitatively similar cell cyc
le effects. Marked divergence was found, however, in the CDKs activate
d by the two cyclins in breast epithelial cells. Cyclin D2 complexes c
ontained a higher Cdk2/Cdk4 ratio than cyclin D1 complexes. The cyclin
D2-associated kinase activity was largely inhibited by Cdk2-specific
inhibitors and could phosphorylate histone H1, a substrate for Cdk2 bu
t not for Cdk4 and Cdk6. Therefore, cyclin D2 preferentially activated
Cdk2 in breast epithelial cells. In contrast, Cdk4 and Cdk6 were pred
ominantly responsible for cyclin D1-associated kinase activity as prev
iously reported. Thus, although cyclins D1 and D2 elicited similar eff
ects on breast epithelial cell cycle progression they appeared to achi
eve this end via activation of different CDKs. This is the first evide
nce of cyclin D2 activating Cdk2 in mammalian cells thus providing fur
ther evidence that D-type cyclins are not necessarily redundant.